公开(公告)号：US12180192B2

公开(公告)日：2024-12-31

申请号：US17330232

申请日：2021-05-25

Applicant: ALIGOS THERAPEUTICS, INC.

Inventor： Koen Vandyck ,  Pierre Jean-Marie Bernard Raboisson ,  David McGowan ,  Jerome Deval

IPC: C07D403/10 ,  C07D401/10 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD  (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.

公开(公告)号：US12065428B2

公开(公告)日：2024-08-20

申请号：US17932218

申请日：2022-09-14

Applicant: Aligos Therapeutics, Inc. ,  Katholieke Universiteit Leuven

Inventor： Dorothée Alice Marie-Eve Bardiot ,  Koen Vandyck ,  Sandro Boland ,  Antitsa Dimitrova Stoycheva ,  Arnaud Didier Marie Marchand ,  Pierre Jean-Marie Bernard Raboisson ,  Leonid Beigelman

IPC: C07D401/14 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D487/04

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D487/04

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240182444A1

公开(公告)日：2024-06-06

申请号：US18487809

申请日：2023-10-16

Applicant: Aligos Therapeutics, Inc. ,  Katholieke Universiteit Leuven

Inventor： Dorothée Alice Marie-Eve Bardiot ,  Sandro Boland ,  Arnaud Didier Marie Marchand ,  Koen Vandyck ,  David McGowan ,  Leonid Beigelman

IPC: C07D401/12 ,  A61P31/14 ,  C07D403/12 ,  C07D471/04 ,  C07D491/04

CPC classification number: C07D401/12 ,  A61P31/14 ,  C07D403/12 ,  C07D471/04 ,  C07D491/04

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240109871A1

公开(公告)日：2024-04-04

申请号：US18486759

申请日：2023-10-13

Applicant: Aligos Therapeutics, Inc. ,  Katholieke Universiteit Leuven

Inventor： Koen Vandyck ,  Dorothée Alice Marie-Eve Bardiot ,  Pierre Jean-Marie Bernard Raboisson ,  Leonid Beigelman ,  Antitsa Dimitrova Stoycheva ,  Sandro Boland ,  Arnaud Didier Marie Marchand

IPC: C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D487/04 ,  C07D491/107 ,  C07D498/04

CPC classification number: C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D487/04 ,  C07D491/107 ,  C07D498/04

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240018126A1

公开(公告)日：2024-01-18

申请号：US18347099

申请日：2023-07-05

Applicant: Aligos Therapeutics, Inc. ,  Katholieke Universiteit Leuven

Inventor： Koen Vandyck ,  Dorothée Alice Marie-Eve Bardiot ,  Pierre Jean-Marie Bernard Raboisson ,  Leonid Beigelman ,  Antitsa Dimitrova Stoycheva ,  Sandro Boland ,  Arnaud Didier Marie Marchand

IPC: C07D403/12 ,  A61P31/14

CPC classification number: C07D403/12 ,  A61P31/14

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11845752B2

公开(公告)日：2023-12-19

申请号：US17450808

申请日：2021-10-13

Applicant: ALIGOS THERAPEUTICS, INC.

Inventor： Sandrine Vendeville ,  Yannick Debing ,  Antitsa Dimitrova Stoycheva ,  Pierre Jean-Marie Bernard Raboisson

IPC: A61K31/4985 ,  C07D487/04 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07D519/00

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230390242A1

公开(公告)日：2023-12-07

申请号：US18453887

申请日：2023-08-22

Applicant: ALIGOS THERAPEUTICS, INC. ,  Emory University

Inventor： Sandrine Vendeville ,  David Bernard Smith ,  Leonid Beigelman ,  Vladimir Serebryany ,  Raymond F. Schinazi ,  Franck Amblard ,  Leda Bassit

IPC: A61K31/4025 ,  C07D405/12 ,  A61K31/40 ,  C07D207/34 ,  C07D487/04 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  A61K31/4192

CPC classification number: A61K31/4025 ,  C07D405/12 ,  A61K31/40 ,  C07D207/34 ,  C07D487/04 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  A61K31/4192

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230365970A1

公开(公告)日：2023-11-16

申请号：US18361363

申请日：2023-07-28

Applicant: Aligos Therapeutics, Inc.

Inventor： Leonid Beigelman ,  Vivek Kumar Rajwanshi ,  Markus Hossbach ,  Rajendra K. Pandey ,  Jin Hong ,  Laxman Eltepu ,  Saul Martinez Montero ,  N. Tilani S. De Costa

IPC: C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61P31/20

CPC classification number: C12N15/1131 ,  A61K31/713 ,  A61K45/06 ,  A61P31/20 ,  C12N2310/351 ,  C12N2310/315 ,  C12N2310/14 ,  C12N2320/31 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/322

Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2′-O-methyl nucleotides and 2′-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5′-stabilized end cap; and (b) a short interfering nucleic acid (siNA).

公开(公告)号：US20230065527A1

公开(公告)日：2023-03-02

申请号：US17444947

申请日：2021-08-12

Applicant: Aligos Therapeutics, Inc.

Inventor： Tongfei Wu ,  Pierre Jean-Marie Bernard Raboisson ,  Francois Gonzalvez ,  Antitsa Dimitrova Stoycheva ,  Jerome Deval ,  Cheng Liu ,  Qingling Zhang

IPC: C07D487/10 ,  C07D519/00 ,  C07D401/14 ,  C07D491/107 ,  C07D491/048 ,  C07D471/04

Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

公开(公告)号：US11549110B2

公开(公告)日：2023-01-10

申请号：US17672268

申请日：2022-02-15

Applicant: Aligos Therapeutics, Inc.

Inventor： Leonid Beigelman ,  Vivek Kumar Rajwanshi ,  Markus Hossbach ,  Rajendra K. Pandey ,  Jin Hong ,  Laxman Eltepu ,  Saul Martinez Montero ,  N. Tilani S. De Costa

IPC: C12N15/113 ,  A61P31/20 ,  A61K31/713 ,  A61K45/06

Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2′-O-methyl nucleotides and 2′-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5′-stabilized end cap; and (b) a short interfering nucleic acid (siNA).